Morgan Stanley Maintains Overweight on Crinetics Pharmaceuticals, Raises Price Target to $70
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Jeffrey Hung maintains an Overweight rating on Crinetics Pharmaceuticals (NASDAQ:CRNX) and raises the price target from $50 to $70.
May 23, 2024 | 3:23 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Morgan Stanley analyst Jeffrey Hung maintains an Overweight rating on Crinetics Pharmaceuticals and raises the price target from $50 to $70.
The raised price target from $50 to $70 by a reputable analyst at Morgan Stanley is likely to positively impact investor sentiment and drive the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100